Nuvation Bio Shares Rise on Promising Safusidenib Data and Pivotal Trial Plans

Shares of Nuvation Bio Inc. (NYSE:NUVB) rose 7% on Monday after the company announced encouraging updated data from a Phase 2 trial of its cancer drug, safusidenib, and revealed plans to expand its clinical program with two new studies.

Updated Phase 2 Results

Nuvation Bio reported updated results from its Phase 2 (J201) study of safusidenib in patients with grade 2 IDH1-mutant glioma who had not previously received chemotherapy or radiotherapy. According to the company, the data from 27 patients in Japan showed strong and durable clinical activity after a median follow-up of 38.8 months.

Key findings from the study include:

• A confirmed objective response rate (ORR) of 52%.
• A 36-month progression-free survival (PFS) rate of 79%.
• The median progression-free survival was not reached during the follow-up period.

Nuvation Bio also noted that only one patient who had previously responded to the treatment experienced subsequent disease progression, and no new safety signals were identified.

Strategic Trial Expansion

Ad

Building on these results, the company announced plans for two new clinical trials. The first is a pivotal Phase 3 study that will enroll approximately 140 patients with grade 2 IDH1-mutant glioma outside the United States. This trial will be conducted in regions where a competing therapy, vorasidenib, is not yet approved or accessible, with progression-free survival as the primary endpoint.

The second study is a Phase 2 trial in the U.S. that will enroll up to 40 patients with grade 2 or 3 IDH1-mutant glioma whose disease has progressed after treatment with vorasidenib. This study is designed to evaluate safusidenib's potential in a second-line setting, with objective response rate as its primary endpoint.

Market Context

Safusidenib is an investigational, oral inhibitor of mutant IDH1, a gene mutation found in a specific type of brain tumor. The initiation of a pivotal Phase 3 trial is a critical step toward seeking regulatory approval. By targeting patients who have progressed on other treatments and operating in markets where competitors are not yet present, Nuvation Bio is pursuing a multi-pronged strategy to establish safusidenib's position in the market for glioma therapies.

In the U.S., nearly 2,500 people are diagnosed with IDH-mutant gliomas each year, with over 95% of these cases involving a mutation in the IDH1 gene, representing the target patient population for this therapy.